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Abstract
BACKGROUND: Warfarin is the mainstay of anticoagulant therapy to prevent thromboembolism in atrial fibrillation 
(AF). It has a narrow therapeutic window, rendering monitoring prothrombin time necessary using the international 
normalized ratio (INR). However, INR value is not always correlated with the clinical risk of bleeding. 
AIM: We aimed to monitor plasma warfarin concentration and to analyze its correlation with bleeding events in 
Indonesian patients of Minangkabau ethnicity with AF.
METHODS: We consecutively recruited outpatients with AF from January to November 2017 at a tertiary hospital 
in West Sumatera, Indonesia. At the time of the study, patients had received at least 5 weeks of warfarin. Their 
characteristics were obtained from medical records, and INR data were collected. Warfarin plasma concentration 
was analyzed using high-performance liquid chromatography.
RESULTS: There were a total of 45 patients (25 males and 20 females; mean age 54.6 years). The number of 
patients with INR value lower than, within, and higher than target value (2.0–3.0) was 25, 12, and 8, respectively. 
Half of the patients (n = 23; 51.1%) had subtherapeutic plasma warfarin levels and nearly half (n = 20; 44.4%) of the 
patients had therapeutic plasma warfarin levels. INR value was not significantly correlated with plasma warfarin level 
(r = 0.273; p = 0.07). Bleeding events occurred in 14 patients. INR value was not significantly different (p = 0.12), 
while the plasma warfarin level was marginally significantly different (p = 0.05) between those with bleeding and no 
bleeding events.
CONCLUSION: Neither warfarin plasma concentration nor INR was correlated with bleeding events in Indonesian 
patients of Minangkabau ethnicity with AF.
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Introduction
Atrial fibrillation (AF) is the most common type 
of arrhythmias and the global burden of AF is increasing 
progressively [1]. The prevalence of AF in some 
countries in Europe ranges from 1.9% to 2.9% [2]. The 
incidence rates in developed regions were significantly 
higher compared with developing countries [1]. 
However, AF prevalence in Indonesian National Heart 
Center in 2013 was 9.8% [3]. The high prevalence of 
AF makes the treatment of AF and factors contributing 
to treatment efficacy a critical field to study in Indonesia.
Arrhythmic, particularly AF, patients were 
commonly treated with the oral anticoagulant warfarin. 
Warfarin has a narrow therapeutic index. Furthermore, 
warfarin binds strongly to albumin; therefore, it may 
shift the bond of other drugs to albumin when given 
simultaneously, thus reducing the effectiveness of 
other medications [4]. The amount of administered 
dose must be individualized by considering each 
patient’s clinical features, by measuring prothrombin 
time periodically, and by noting the tendency for the 
occurrence of bleeding [5]. The therapeutic range of 
oral anticoagulants is expressed by the International 
Normalized Ratio (INR) calculated based on 
prothrombin time. In general, the INR value of 2.0–3.0 
is considered within the therapeutic range. INR value is 
used as a guide for dose adjustment in patients receiving 
warfarin [6]. Patients with periodical INR value within 
the therapeutic range 70% of the time or more had a 
significantly reduced risk of stroke [7]. Determination of 
warfarin plasma concentration is an objective procedure 
to ascertain drug concentration in the blood. Some 
patients may show resistance to warfarin and, thus, 
may require an increased dose. Warfarin resistance 
is shown to be associated with genetic abnormalities 
or the presence of genetic polymorphisms, particularly 
on CYP2C9 and VKORC1 [8], [9]. Asians, African-
Americans, and Native Americans combined had 
lower mean time in therapeutic range compared with 
European patients receiving warfarin [10]. Ethnic-
specific dosing algorithms are thought to be crucial 
in pharmacogenetics-guided warfarin therapy [11]. 
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However, first, we need to ascertain warfarin plasma 
level in the ethnic group of interest.
Up until now, there is no data on warfarin 
plasma concentration in the Indonesian population 
of Minangkabau ethnic origin suffering from AF. As 
Indonesia is a multi-ethnic country, ethnic-specific 
information is valuable in identifying pharmacokinetics 
variation among patients. The setting of the current 
study was a general referral hospital in the capital of 
West Sumatera Province, where Minangkabau ethnic 
resides. Most patients’ medication was covered by 
a national health insurance system. Patients were 
referred by primary care physicians to the cardiology 
department of the hospital to receive specialized care for 
their AF. In this study, we investigated warfarin plasma 
concentration to identify pharmacokinetics variation 
that might impact warfarin efficacy in our patients.
Materials and Methods
Study subjects
This study was a cross-sectional study 
conducted from January to November 2017 in 
Indonesian patients of Minangkabau ethnicity with 
AF receiving warfarin therapy at a tertiary hospital in 
West Sumatra, Indonesia. The study was performed 
according to the Declaration of Helsinki and approved 
by the Ethical Committee (Institutional Review Board) 
of the Faculty of Medicine, Andalas University (Ref 
No. 177/KEP/FK/2017). Blood samples used in 
the study were collected at a single time point from 
patients attending outpatient clinic at the Department of 
Cardiology and Vascular Medicine, M. Djamil General 
Hospital, Padang, West Sumatra, who had received 
oral anticoagulant warfarin for at least 5 weeks. Patients 
were male or female above 18 years old diagnosed with 
AF based on standard diagnostic criteria [12]. Those 
with impaired liver and kidney function and pregnancy 
were excluded from the study.
Bleeding event as the side effect of oral 
anticoagulant therapy was defined according to 
the Bleeding Academic Research Consortium 
definition [13] and it was assessed by history taking at 
the time of sample collection. The bleeding event in this 
study was either Type 0 (no evidence of bleeding) or 
Type 1 (bleeding that is not actionable and does not 
cause the patient to seek treatment by a health-care 
professional) during the past 5 weeks. Patients’ 1-year 
risk of major bleeding was assessed by calculating 
their hypertension, abnormal liver/renal function, 
stroke, bleeding history or predisposition, and labile 
INRs (HAS-BLED) score [14]. All patients were taking 
medications other than warfarin, and these drugs were 
listed and checked for their interaction with warfarin.
Plasma warfarin analysis
Plasma warfarin analysis was performed 
by Pharmametric Laboratory, Jakarta. The method 
was as followed. Three milliliters of blood was drawn 
from the vein by using Vacutainer®, inverted and 
centrifuged at 3,000 rpm for 10 min. Plasma was 
immediately separated, aliquoted, and stored at −20°C 
for <1 month before analysis. High-performance 
liquid chromatography was used to measure plasma 
warfarin concentration using a C18 column with 
mobile phase acetonitrile and 0.5% triethylamine at a 
ratio of 28:72; pH 6.5; and flow velocity 1.0 ml/min at 
386 nm  [15], [16], [17].
Statistical analysis
Categorical data were presented in a frequency 
distribution, and continuous data were presented in mean, 
median, and range. The correlation of administered 
warfarin dose with plasma warfarin level and INR value 
was analyzed by Spearman’s rank correlation due to the 
non-normal distribution of the data. The difference in INR 
and plasma warfarin levels in subjects with and without 
bleeding events was analyzed by the Mann–Whitney 
U test. Statistical significance was set at p < 0.05. All 
statistical analyses were performed using IBM® SPSS® 
Statistics ver.19 (IBM, US).
Results
There were 45 subjects with AF who met 
inclusion criteria and agreed to participate in the study 
with characteristics, as shown in Table 1. The median 
warfarin plasma concentration was 0.94 µg/ml with a 
median maintenance dose of 2.5 mg/day. More than 
half (55.6%) of patients had INR value <2.0 and only 
28.9% of patients reached the desirable INR value of 
2.0–3.0, while the rest (15.6%) showed value >3.0 [7].
Warfarin dose was found to be statistically 
significantly correlated with plasma warfarin level, 
albeit with moderate positive correlation (r = 0.459, 
p = 0.002; Figure 1a). However, warfarin dose and 
plasma warfarin levels were not significantly correlated 
with INR (r = −0.032, p = 0.83; Figure 1b and r = 0.273, 
p = 0.07; Figure 1c, respectively).
Figure 1: Correlations of warfarin dose with plasma warfarin level 
(a) and international normalized ratio (INR) (b), and correlation of 
plasma warfarin level with INR (c) in 45 patients with atrial fibrillation
cba
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To explore the relationship between bleeding 
event occurrence with plasma warfarin level and INR in 
our subjects, we compared plasma warfarin level and 
INR in those without (n = 24) and with (n = 14) bleeding 
events. Patients whose information on bleeding events 
unavailable (n = 7) were not included in the analysis. 
Those with bleeding events had lower plasma warfarin 
levels (p = 0.05) and higher INR (p = 0.12), albeit 
statistically non-significant, compared to those without 
bleeding events (Figure 2).
Figure 2: Association of plasma warfarin level (a) and international 
normalized ratio (b) with occurrence of bleeding event in 45 patients 
with atrial fibrillation
a b
To predict major bleeding risk in anticoagulated 
AS patients, we calculated the HAS-BLED score [14] 
and presented the result in Table 2. More than half 
(57.8%) of the patients were categorized to moderate 
risk (HAS-BLED score 1–2) and the rest (42.2%) were 
categorized to a high risk of major bleeding (HAS-BLED 
score ≥3).
Table 2: Bleeding risk in AF patients based on HAS-BLED* 
score
HAS-BLED score Frequency Percent Risk category
1 9 20 Moderate
2 17 37.8
3 16 35.6 High
4 1 2.2
5 1 2.2
6 1 2.2
Total 45 100
*HAS-BLED: Hypertension, abnormal liver/renal function, stroke, bleeding history or predisposition, labile 
INRs, elderly (age>65), drugs or alcohol. INR: International normalized ratio, AF: Atrial fibrillation.
To consider the possible pharmacokinetic 
interaction between warfarin and other drugs affecting 
warfarin plasma levels, we have compiled all the drugs 
administered to the patients in Table 3. There were four 
drugs that might have a major and a moderate interaction 
with warfarin, and there were six drugs that might have 
minor interaction with warfarin, taken by the patients.
Table 3: List of drugs administered to the warfarin-taking 
patients
Drug class Drug name Known 
interaction 
with warfarin
Number of 
patients taking 
the drug
Antiplatelet Acetosal Major 5
Cilostazol Major 1
Clopidogrel Major 1
Beta-blocker Bisoprolol No 40
Carvedilol No 4
Propranolol Minor 1
Loop-diuretic Furosemide Minor 29
Potassium-sparing diuretic Spironolactone Minor 21
Angiotensin receptor blocker Candesartan No 8
Telmisartan Minor 3
Valsartan No 1
ACE-inhibitor Ramipril No 12
Lisinopril No 1
Calcium-channel blocker Amlodipine No 4
Nifedipine No 1
Cardiac glycoside Digoxin No 5
Statin Atorvastatin Minor 11
Simvastatin Minor 1
Nitrate Isosorbide dinitrate No 2
Uric acid medication Allopurinol Moderate 3
Colchicine No 1
Proton-pump inhibitor Lansoprazole Moderate 12
Omeprazole Moderate 1
Mucosal protector Sucralfate Moderate 2
Laxative Psyllium No 1
Laxadine™ No 1
Antibiotics Ciprofloxacin Major 1
Benzodiazepine Clobazam No 1
Others Vitamin B No 5
Folic acid No 1
Acetyl cysteine No 1
Discussion
The mean warfarin plasma concentration of 
patients with AF in this study was 1.1 ± 0.6 (range, 
Table 1: Characteristics of subjects
Characteristics n (%) AMa GMb Median Min Max
Age (year) 45 (100) 54.6 25 80
Sex
Male 25 (55.6)
Female 20 (44.4)
Body mass index (kg/m2) 45 (100) 22.9 17.6 29.3
Level of education
Primary 14 (31.1)
Secondary 28 (62.2)
Graduate/postgraduate 3 (6.7)
Occupation
Civil servant 5 (11.1)
Self-employed 13 (28.9)
Housewife 18 (40.0)
Retiree 9 (20.0)
Warfarin dose (mg/day) 45 (100) 2.9 2.6 2.5 0.8 7.0
INR 45 (100) 2.1 1.9 1.8 0.9 5.3
<2.0 25 (55.6)
2.0–3.0 13 (28.9)
>3.0 7 (15.6)
Plasma warfarin (µg/ml) 45 (100) 1.1 0.90 0.94 0.1 3.1
<1.0 23 (51.1)
1.0–2.0 20 (44.4)
>2.0 2 (4.4)
Side effect occurrence 38 (100)
None 24 (63.2)
Bleeding 14 (36.8)      
aArithmetic mean
bGeometric mean
INR: International normalized ratio.
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0.1–3.1) µg/ml. It was achieved with a maintenance 
dose of 2.9 ± 1.3 (range, 0.8–7.0) mg/day. This result is 
higher than that of a study in Chinese patients with heart 
valve replacement within 1 month of post-operation, 
where the mean of warfarin plasma concentration was 
0.6 ± 0.12 µg/ml [18]. However, our finding is similar to a 
study in Korean patients (1.3 ± 0.5 µg/ml) administered 
a higher maintenance dose of 4.1 ± 1.3 mg/day (range, 
1.7–8.0 mg/day) than our patients [19]. Polymorphisms 
in a gene such as VKORC1, CYP2C9 [8], [9], [10], [11], 
and CYP4F2 [20] may contribute to the differences in 
plasma warfarin levels.
Warfarin is a Vitamin K antagonist with the 
anticoagulant effect mediated through the prevention of 
activation of Vitamin K dependent coagulation factors 
(factor II, VII, IX, and X) [21] age [22], fat-free mass [23], 
Vitamin K-rich foods, and coadministered drugs [24] 
are determinants of warfarin pharmacokinetics. It is 
estimated that pharmacokinetics factors determine up to 
40% of warfarin maintenance dose variability [24], [25]. 
We have listed coadministered drugs in our patients 
and found that eight patients were taking drugs with 
significant interaction with warfarin. This possible 
interaction may influence the correlation between 
plasma warfarin levels and INR. Furthermore, genetic 
variations of VKORC1 and Vitamin K intake influence 
warfarin dose and anticoagulation response [26]. With 
a narrow therapeutic window and a high inter- and 
intra-individual variability, warfarin use needs careful 
laboratory monitoring and dose adjustment to gain 
antithrombotic protection while minimizing the 
bleeding risk.
Warfarin dose was found to be correlated 
with plasma warfarin levels. However, plasma warfarin 
level was not significantly correlated with INR, despite 
a trend of increasing INR with increasing plasma 
warfarin level. These results confirmed the finding of 
a previous study where the INR is poorly dependent 
on warfarin concentration [27]. Previous studies in 
Indonesians receiving low-dose warfarin therapy found 
that a high INR is associated with polymorphisms in 
VKORC1 and CYP2C9 [28], and both genes showed 
significant association with warfarin sensitivity [9]. 
Whether these major genetic factors played a role in 
the pharmacokinetics and/or pharmacodynamics in our 
subjects, remain to be elucidated.
This study finds that less than a third of 
patients who received doses of 0.8–7.0 mg/day of 
warfarin had INR value within the optimal warfarin 
therapy range (2.0–3.0). One study reported that 
stable anticoagulation was achieved in 80% of patients 
who received doses of 2–5 mg/day of warfarin [29]. 
Previous studies had demonstrated the importance of 
maintaining a stable INR value between 2.0 and 3.0 for 
reducing strokes and mortality in patients with AF [7]. 
When INR value remained within the therapeutic range 
of more than 70% of the time, there is a substantially 
lower risk of stroke [30]. A previous study showed that 
INR value 2.0–3.0 was associated with a reduced 
risk of clinically significant bleeding [31]. In this study, 
the INR value was not correlated to the incidence 
of bleeding. Despite the HAS-BLED score showing 
our patients having moderate to high risk of major 
bleeding, the bleeding episodes in this study were 
minor, and HAS-BLED score was not correlated with 
plasma warfarin level (data not shown). Diets, age, 
drug interactions, and genetic polymorphisms are 
known to link with warfarin metabolism. In this study, 
age was not associated with INR or plasma warfarin 
(data not shown).
The limitation of this study was that data were 
obtained from a single center with a small number of 
patients. Nevertheless, this is the first plasma warfarin 
monitoring study in warfarin-treated AF patients from 
the Indonesian ethnic of Minangkabau. The current 
study did not encompass patients’ clinical outcomes on 
follow-up, and therefore further studies are warranted.
Conclusion
Neither warfarin plasma concentration nor 
INR was correlated with bleeding events in Indonesian 
patients of Minangkabau ethnicity with AF. Future 
endeavor is recommended in a more extensive 
study to explore the genetic variants contributing to 
warfarin pharmacokinetics/pharmacodynamics in this 
population.
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